ES2440371B1 - Cells, cell lines and non-human animal model, for the determination of therapeutic agents. - Google Patents

Cells, cell lines and non-human animal model, for the determination of therapeutic agents. Download PDF

Info

Publication number
ES2440371B1
ES2440371B1 ES201230999A ES201230999A ES2440371B1 ES 2440371 B1 ES2440371 B1 ES 2440371B1 ES 201230999 A ES201230999 A ES 201230999A ES 201230999 A ES201230999 A ES 201230999A ES 2440371 B1 ES2440371 B1 ES 2440371B1
Authority
ES
Spain
Prior art keywords
cells
cell lines
animal model
human animal
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201230999A
Other languages
Spanish (es)
Other versions
ES2440371A1 (en
Inventor
Ruth Rubio Amador
René RODRÍGUEZ GONZÁLEZ
Pablo MENENDEZ BUJÁN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Publica Andaluza Progreso y Salud filed Critical Fundacion Publica Andaluza Progreso y Salud
Priority to ES201230999A priority Critical patent/ES2440371B1/en
Priority to PCT/ES2013/070444 priority patent/WO2014001596A1/en
Publication of ES2440371A1 publication Critical patent/ES2440371A1/en
Application granted granted Critical
Publication of ES2440371B1 publication Critical patent/ES2440371B1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Células, líneas celulares y modelo animal no humano, para la determinación de agentes terapéuticos.#La presente invención describe células madre mesenquimales aisladas diferenciadas a progenitor osteogénico, modificadas genéticamente mediante la deleción de las secuencias o de un fragmento de las secuencias que codifican para la proteína p53 y la proteína Rb. Las células descritas en la presente invención tienen además la capacidad de originar tumores in vivo del tipo osteosarcoma. En la presente invención se describen también las líneas y poblaciones celulares, así como un modelo animal no humano al que se le han implantado dichas células madre osteosarcoma-like. Del mismo modo, la presente invención describe el método de obtención de dichas células y usos, preferentemente para el screening de agentes útiles en el tratamiento y/o prevención del sarcoma.Cells, cell lines and non-human animal model, for the determination of therapeutic agents. # The present invention describes isolated mesenchymal stem cells differentiated to osteogenic progenitor, genetically modified by deleting the sequences or a fragment of the sequences encoding the p53 protein and Rb protein. The cells described in the present invention also have the ability to cause tumors in vivo of the osteosarcoma type. In the present invention cell lines and populations are also described, as well as a non-human animal model to which said osteosarcoma-like stem cells have been implanted. Similarly, the present invention describes the method of obtaining said cells and uses, preferably for screening agents useful in the treatment and / or prevention of sarcoma.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

Claims (1)

imagen1image 1 imagen2image2
ES201230999A 2012-06-28 2012-06-28 Cells, cell lines and non-human animal model, for the determination of therapeutic agents. Withdrawn - After Issue ES2440371B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230999A ES2440371B1 (en) 2012-06-28 2012-06-28 Cells, cell lines and non-human animal model, for the determination of therapeutic agents.
PCT/ES2013/070444 WO2014001596A1 (en) 2012-06-28 2013-06-28 Cells, cell lines and non-human animal model for determining therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230999A ES2440371B1 (en) 2012-06-28 2012-06-28 Cells, cell lines and non-human animal model, for the determination of therapeutic agents.

Publications (2)

Publication Number Publication Date
ES2440371A1 ES2440371A1 (en) 2014-01-28
ES2440371B1 true ES2440371B1 (en) 2014-11-11

Family

ID=49782314

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230999A Withdrawn - After Issue ES2440371B1 (en) 2012-06-28 2012-06-28 Cells, cell lines and non-human animal model, for the determination of therapeutic agents.

Country Status (2)

Country Link
ES (1) ES2440371B1 (en)
WO (1) WO2014001596A1 (en)

Also Published As

Publication number Publication date
WO2014001596A1 (en) 2014-01-03
ES2440371A1 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
CY1125092T1 (en) MEDICAL USE RELATING TO TELOMERE EXTENSION
CY1123735T1 (en) PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN THE REGULATION OF GLIOGENESIS
AR092779A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ANTIBODIES THAT JOIN TAU PROTEIN CONFORMERS
UY33826A (en) UNION PROTEINS WITH TRIVARIABLE DOMAINS AND ITS USES
EA201700181A1 (en) COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
DE112012006327A5 (en) Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
ECSP14016014A (en) SYNTHETIC APELLIN MIMETICS FOR THE TREATMENT OF HEART FAILURE
BR112014031874A2 (en) method for preparing high concentration stem cells
CU24206B1 (en) FUSION PROTEINS THAT INCLUDE USEFUL FIBROBLAST GROWTH FACTOR IN METABOLIC DISORDERS
CL2015002941A1 (en) Therapeutic uses of empaglifozin
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
EA201791577A1 (en) CONNECTING WITH EGFR AND C-MET MOLECULES WITH FIBRONECTIN TYPE III DOMAINS
CL2014002846A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins.
MX2020011415A (en) Methods of using zscan4 for rejuvenating human cells.
CO2017000346A2 (en) Aβ protofibril binding antibodies
WO2015191934A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
PH12016502024A1 (en) Tonoplast proton/sugar antiporter proteins and the use thereof to increase the saccharose concentration in a saccharose storage organ of plants
MX2018006226A (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential.
ES2482666B1 (en) Use of strain CECT 7426 to cause quorum quenching of the auto-inducer signal-2 (AI-2)
MX2016000423A (en) Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid.
ES2440371B1 (en) Cells, cell lines and non-human animal model, for the determination of therapeutic agents.
CL2017002326A1 (en) Treatment of patients with type 2 diabetes mellitus
WO2014142760A3 (en) Re-trafficking of herg reverses long qt syndrome 2 phenotype in human ips-derived cardiomyocytes
EP4218777A3 (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2440371

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141111

FA2A Application withdrawn

Effective date: 20150317